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Abstract
Purpose Aim of this study was to demonstrate that MDCO-
216 (human recombinant Apolipoprotein A-I Milano) does
not induce adverse immunostimulation, in contrast to its pre-
decessor, ETC-216, which was thought to contain host cell
proteins (HCPs) that elicited an inflammatory reaction.
Methods Data were taken from a clinical trial in which 24
healthy volunteers (HV) and 24 patients with proven stable
coronary artery disease (sCAD) received a single intravenous
dose of MDCO-216, ranging 5–40 mg/kg. Additionally,
whole blood from 35 HV, 35 sCAD patients and 35 patients
requiring acute coronary intervention (aCAD group) was
stimulated ex vivo with MDCO-216 and ETC-216.
Results No inflammatory reaction was observed in HV and
sCAD patients following MDCO-216 treatment, judging by
body temperature, white cell counts, neutrophil counts, C-
reactive protein, circulating cytokines (IL-6, TNF-α), and ad-
verse events. In the ex vivo experiment, the geometric means
(SD) of the ratio of MDCO-216 stimulated IL-6 over back-
ground levels were 0.8 (1.9), 0.7 (1.5), 1.0 (2.0) for respectively
HV, sCAD, aCAD. The corresponding ETC-216 stimulated
values were 15.8 (2.9), 9.5 (3.6), 3.8 (4.0). TNF-α results were
comparable. Because many ETC-216 stimulated samples had
cytokine concentrations >ULOQ, ratios were categorised and
marginal homogeneity of the contingency table (MDCO-216
versus ETC-216) was assessed with the Stuart-Maxwell test. P-
values were ≤0.0005 for all populations.
Conclus ions MDCO-216 did not induce adverse
immunostimulation in HV and sCAD patients, in contrast to
ETC-216. Results from the ex vivo stimulation suggests the same
holds true for aCAD patients.
Keywords Immunostimulation .MDCO-216 .ETC-216 .Ex
vivo stimulation . Apolipoprotein A-IMilano
Introduction
Over the past decades high density lipoprotein (HDL) and
Apolipoprotein A-I (ApoA-I) have been targeted in the pursuit
of therapies that reduce the risk of cardiovascular events [1].
One of these therapies is ApoA-I Milano (ApoA-IM), a natu-
rally occurring mutant of ApoA-I which was found to be as-
sociated with cardioprotective effects [2, 3].
Because of these effects, a human recombinant ApoA-IM,
codenamed ETC-216, was developed by Esperion Therapeutics
in the nineties. In vitro results with recombinant ApoA-IM dem-
onstrated enhanced reverse cholesterol transport, and in animal
models regression of atherosclerotic plaques was observed [4].
ETC-216 induced profound lipid changes in the initial phase I
study (unpublished results), resulting in a lipid profile that closely
resembled carriers of the ApoA-IM mutation. However, dose-
dependent increases in neutrophils, paralleling decreases in
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lymphocytes were observed as well. This phenomenon was first
seen in males at a dose level of 50 mg/kg (neutrophil increase
>200%), and in females at a dose level of 15 mg/kg (increase
~80%).
After decreasing the infusion rate from 1.67 mg/kg/min for
males and females to 1.25 mg/kg/min for males and 0.83 mg/
kg/min for females, a dose of 100 mg/kg in males and a dose
of 50 mg/kg in females was required to induce equal changes
in neutrophils and lymphocytes (Fig. 1). Maximum change
from baseline in WBC counts was observed at 4 h after the
start of the infusion, returning to baseline twenty hours later.
A similar dose-dependent pattern was seen for the adverse
events reported within 24 h of administration. Following
15 mg/kg ETC-216 in healthy females, and following
50 mg/kg ETC-216 in healthy males respectively 2/3 and
1/3 participants developed gastrointestinal symptoms (nausea,
vomiting, diarrhoea). Lowering the infusion rate reduced the
incidence of these events; however, at 100 mg/kg 3/3 partici-
pants reported gastrointestinal symptoms. These events oc-
curred approximately 2–4 h after infusion and were some-
times accompanied by systemic symptoms, such as diaphore-
sis and changes in body temperature.
In the subsequently executed phase II study in patients with
an acute coronary syndrome (ACS) [5], it was shown that
doses up to 45 mg/kg ETC-216 were associated with a signif-
icant regression of the atherosclerotic burden. Not many ad-
verse events were reported, although in a single patient a pos-
sible hypersensitivity reaction was noted, consisting of gastro-
intestinal complaints, rash, chills, and diaphoresis.
Despite the overall promising results, clinical development
was halted after a serious adverse reaction had occurred early
during the third clinical trial in one patient. When adminis-
tered intravenously within the hour after percutaneous coro-
nary intervention (PCI), a patient developed a severe reaction
during infusion, consisting of flushing, chills, hypotension,
ultimately leading to multi-organ failure.
Because the available data pointed to a systemic inflamma-
tory reaction, contamination of the infused drug product was
considered. Careful evaluation of the entire manufacturing
process revealed that ETC-216 contained small quantities of
residual host cell proteins (HCP) that elicited an immune re-
sponse (unpublished results). Importantly, these effects
remained undetected during preclinical development, and be-
came apparent only when the drug was administered to
humans, even though all appropriate standards and guidelines
had been followed.
A component of the HCP in the ETC-216 drug product was
demonstrated to be flagellin, using an assay based on the human
toll-like receptor (TLR)-5 [6]. Other impurities included an
oligopeptide binding protein (OppA), a dipeptide binding protein
(DppA), and maltose-binding periplasmic protein (MalE) [7].
Due to the physical characteristics of ApoA-IM reducing
these impurities proved difficult and was ultimately achieved
by selectively deleting the genes encoding some of the con-
taminating proteins and by other significant improvements to
the downstream manufacturing process [7–9]. Hereafter, re-
combinant ApoA-IM was reintroduced as MDCO-216 by the
Medicines Company and was tested in healthy volunteers and
in patients with stable coronary artery disease (CAD) [10].
This article describes the results of ex vivo stimulation of
whole blood samples with ETC-216 and MDCO-216 in three
populations (healthy volunteers, patients with stable CAD, and
patients with acute CAD). The aim was to characterise the dif-
ferences in cytokine releasing potential between both drug prod-
ucts. To confirm that the HCPs that induced an inflammatory
response were indeed successfully eliminated, the in vivo expe-
rience with MDCO-216 was compared to the ex vivo results.
Methods
Populations
Table 1 summarises the inclusion criteria of the investigated
populations; these encompass both the in vivo and ex vivo
exposed populations. Data on the in vivo experience with
MDCO-216 came from a randomised, double-blind phase I
clinical trial [10], in which 24 healthy volunteers (HV) and 24
patients with stable CAD (sCAD) received a single intrave-
nous dose of 5–40 mg/kg MDCO-216 or placebo.
All subjects enrolled in this trial were also challenged
ex vivo with both ETC-216 and MDCO-216, together with
those screened for participation and meeting the criteria as
listed in Table 1. All trial participants provided written in-
formed consent.
Acute CAD (aCAD) patients were recruited from patients
with an acute coronary syndrome (ACS) who presented to the
department of cardiology of the Leiden University Medical
Center (Leiden, The Netherlands) for a percutaneous coronary
intervention (PCI). After verbal approval the blood sample for
ex vivo stimulation was collected alongside the routine clini-
cal samples. Written consent was asked at a later stage; if not
provided, the blood sample was destroyed and not analysed.
Approval was obtained from independent ethics commit-
tees for all trials and related procedures prior to the start of the
respective studies, in accordance with pertaining legal
requirements.
Ex Vivo Exposure
Ex vivo stimulations were performed at Good Biomarker
Sciences (GBS, Leiden, The Netherlands). Heparinised whole
blood samples (18 mL, BD Vacutainer, Becton Dickinson,
Breda, The Netherlands) were collected and incubated for
4 h at 37 °C in a humidified atmosphere with 5% CO2, before
flash-freezing the supernatant for subsequent analysis. Tested
382 Cardiovasc Drugs Ther (2017) 31:381–389
conditions were 0.5 mg/mL ETC-216 (The Medicines
Company, Zürich, Switzerland), 0.5 mg/mL MDCO-216
(The Medicines Company, Zürich, Switzerland), 2 ng/mL li-
popolysaccharide (LPS) gel extracted from E. coli serotype
O111:B4 (Sigma-Aldrich, St. Louis MO, USA), blanc
(unstimulated control). The concentration of 0.5 mg/mL for
ETC-216 and MDCO-216 correlates with the maximum plas-
ma concentration achieved following an in vivo dose of 20–
30 mg/kg. LPS concentration is based on the EC90 of maxi-
mum TNF-α release and serves as a positive control.
Conditions were made in RPMI with 25 mM HEPES and L-
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Fig. 1 In vivo results. Absolute change (median) over time in clinical
markers of inflammation is displayed for placebo and the highest dose
(40 mg/kg) of MDCO-216 in healthy volunteers (HV) and in patients
with stable coronary artery disease (sCAD). As a reference, the median
profiles over time in males in the placebo and highest dose groups from
the (unpublished) phase I ETC-216 trial are projected in the background.
Of note, 75 mg/kg and 100 mg/kg of ETC-216 were administered at half
the infusion rate as was 50 mg/kg of ETC-216 (see main body). Oral
temperature served as body temperature in the ETC-216 phase I trial,
whereas tympanic membrane temperature was used in the MDCO-216
phase I trial
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Bleiswijk, the Netherlands). Final dilution of whole blood
required to achieve the tested concentrations was 10%.
Ex vivo exposure of a subject to MDCO-216 always oc-
curred prior to any in vivo exposure (HV and sCAD). Blood
samples were kept at 37 °C and processed within one hour
after collection, with the exception of the aCAD population,
where an interval of up to 12 h was allowed, to increase the
number of evaluable samples. Additionally, these samples
from aCAD patients were kept at room temperature, since this
reduces cell death and subsequent lack in responsiveness upon
stimulation (data on file).
Safety Assessments
Safety assessments after in vivo exposure were performed at
regular intervals during the follow up period. These consisted
of vital signs, 12-lead electrocardiograms (ECGs), physical
examination, registration of adverse events (AEs), and routine
clinical chemistry and haematology evaluation. Safety blood
samples were collected and analysed in accordance with local
protocols.
Cytokines
TNF-α and IL-6 were quantitated in culture supernatants and
in plasma samples by Good Biomarker Sciences (GBS,
Leiden, The Netherlands). For supernatants a R&D
Quantikine ELISA assay (R&D Systems, Inc., Minneapolis,
United States) was used, and for plasma samples a R&D
Quantikine HS ELISA assay. All samples from one subject
were assayed in one run. LPS stimulated samples were initial-
ly measured after 20-fold and 50-fold dilution for TNFα and
IL-6 respectively in the manufacturer provided diluents. Other
samples were initially measured undiluted. Samples were
remeasured with higher dilution as needed.
TNF-α and IL-6 values in the supernatants were accepted
when duplicates were <20% CV for values within the calibra-
tion range: LLOQ (lower limit of quantitation) 15.6 pg/mL
and 3.1 pg/mL, and ULOQ (upper limit of quantitation)
1000 pg/mL and 300 pg/mL, for TNF-α and IL-6 respectively.
TNF-α and IL-6 values in the plasma samples were accepted
when duplicates were <20% CV for values within the calibra-
tion range: LLOQ 0.5 pg/mL and 0.16 pg/mL, and ULOQ
32 pg/mL and 10 pg/mL, for TNFα and IL-6 respectively.
Statistical Analysis
All available data were included in the analyses unless other-
wise indicated. Values <LLOQ or >ULOQ were replaced by
respectively the LLOQ or ULOQ, as appropriate. Log-
normally distributed parameters were ln-transformed prior to
analysis.
Individual ratios of stimulated cytokine levels over
unstimulated (background) levels were calculated and com-
pared statistically. In case of background levels <LLOQ or
stimulated levels >ULOQ, the corresponding ratio (respec-
tively [stimulated]/LLOQ or ULOQ/[unstimulated]) was
regarded as the lower margin of the interval (calculated ra-
tio,∞] for the purpose of categorical data analysis.
Continuous data were primarily analysed using an analysis
of variance, which could include a covariance analysis to cor-
rect for confounding factors. Contrasts and effects (with 95%
confidence intervals) were calculated as relevant according to
the Tukeymethod. If the assumption of equal variancewas not
Table 1 Investigated populations
HV sCAD aCAD
Inclusion criteria
Age (years) 18–55 45–80 ≥18
Body weight (kg) ≤110 ≤110 –
BMI (kg/m2) 18–25 ≤40 –






– ≥1 year immediately prior to the
revascularisation procedure
Concomitant therapy not allowed, except for
oral contraceptives




In vivo single dose MDCO-216 5–40 mg/kg
(n = 16) or placebo (n = 8) in 2 h
single dose MDCO-216 10–40 mg/kg
(n = 16) or placebo (n = 8) in 2 h
–






Inclusion criteria for the different populations and details of in and ex vivo exposure. aCAD Patients with acute coronary artery disease (CAD); BMI
Body mass index; HV Healthy volunteers; sCAD Patients with stable coronary artery disease (CAD)
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met, multiple Welch’s t-tests were performed to evaluate the
validity of the statistical results.
Categorical data were analysed in a logistic regression
model, which could include a covariance analysis to correct
for confounding factors. For contingency tables, marginal ho-
mogeneity was tested with the Stuart-Maxwell test.
Data analysis was performed with R (v2.15.2, R
Foundation for Statistical Computing, Vienna, Austria, 2012
[R Development Core Team, 2012]). Results are presented as
mean (standard deviation or 95% confidence interval) for con-




In total, 35 HVand 35 sCAD patients, who were screened for
participation in the MDCO-216 phase I clinical trial, had
evaluable results following ex vivo exposure and were includ-
ed in the analysis. Additionally, 38 aCAD patients signed
informed consent and provided a blood sample for ex vivo
testing in the prespecified period (October 2013 toMay 2014),
of whom 35 had evaluable results and were included in the
analysis. Baseline characteristics of the different populations
are presented in Table 2.
Table 3 presents the released IL-6 upon stimulation of
whole blood samples with either ETC-216 or MDCO-216 in
relation to background IL-6 levels. From this table, it is seen
that ETC-216 clearly elicits a cytokine response, especially
when compared to MDCO-216, which seemingly in-
hibits spontaneous (unstimulated) cytokine release, with
a geometric mean ratio of 0.7–1.0, for respectively
sCAD and aCAD. This was not caused by an interfer-
ence of MDCO-216 in the measurement of IL-6, as was
determined by measuring a sample with known cytokine
levels with and without spiking of MDCO-216 just prior
to analysis.
Because many ETC-216 stimulated samples had cytokine
concentrations >ULOQ (e.g. HV: 26 [74.3%] for IL-6 and 20
[57.1%] for TNF-α), preventing the use of an analysis of
variance, the ratios of ETC-216 and MDCO-216 stimulated
over background levels were categorised and marginal homo-
geneity of the contingency table of MDCO-216 versus ETC-
216 was statistically tested with the Stuart-Maxwell test.
Categories were chosen as <0.2, [0.2,0.5), [0.5,1), [1,2),
[2,5), ≥5, based on the fact that virtually all >ULOQ values
resulted in a ratio greater than 5. For IL-6 the thus obtained p-
values under the null hypothesis of marginal homogeneity
were <10−5, <10−5, and 0.0004 for HV, sCAD, and aCAD,
respectively; the corresponding results for TNF-αwere <10−5,
<10−4, and 0.0005, indicating that ETC-216 and MDCO-216
yielded statistically significantly different cytokine responses.
Table 2 Population
characteristics exposed in vivo exposed ex vivo
Parameter HV sCAD HV sCAD aCAD
(n = 24) (n = 24) (n = 35) (n = 35) (n = 35)
Age (year) 26.2 (8.6) 62.8 (7.0) 24.6 (7.5) 64.0 (7.8) 64.4 (12.9)
Height (cm) 175 (8.7) 177 (6.7) 176 (8.7) 177 (6.3) 176 (10.7)
Body weight (kg) 70.0 (11.3) 85.0 (12.8) 69.8 (10.8) 86.5 (13.3) 81.4 (19.2)
BMI (kg/m2) 22.5 (1.8) 27.0 (3.3) 22.3 (1.9) 27.4 (3.3) 26.1 (5.3)
Gender
Female (n) 14 (58%) 1 (4%) 18 (51%) 1 (3%) 11 (31%)
Male (n) 10 (42%) 23 (96%) 17 (49%) 34 (97%) 24 (69%)
Revascularisation procedure
CABG (n) 12 (50%) 14 (40%)
PCI (n) 12 (50%) 21 (60%) 35 (100%)
Coronary involved
Cx (n) 6 (25%) 10 (29%) 15 (43%)
LAD (n) 7 (29%) 8 (23%) 19 (54%)
RCA (n) 6 (25%) 12 (34%) 15 (43%)
Unknown (n) 10 (42%) 13 (37%) 12 (34%)
Characteristics as mean (standard deviation) or number (percentage) of different populations, who were exposed
in vivo toMDCO-216 or who were exposed ex vivo to bothMDCO-216 and ETC-216. aCAD Patients with acute
coronary artery disease (CAD); BMI Body mass index; CABG Coronary artery bypass grafting; Cx Circumflex
artery; HV Healthy volunteers; LAD Left anterior descending artery; PCI Percutaneous coronary intervention;
RCA Right coronary artery; sCAD Patients with stable coronary artery disease (CAD).
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When comparing the different populations, ETC-216 gen-
erally induced lower IL-6 release in the CAD patients than in
healthy volunteers. Lower ratios in the CAD populations were
also obtained for theMDCO-216 stimulated samples, but LPS
exposure resulted in a lower ratio in the aCAD population
only. These differences could not be related to age, weight,
BMI, blood pressure, (differential) leucocyte count, the sever-
ity of the CAD based on total obstruction, the coronary in-
volved, or the type of revascularisation procedure.
The ex vivo results in the aCAD population did not sub-
stantially differ from those obtained in the sCAD population.
However, some acute CAD patients had considerably higher
background (unstimulated) IL-6 levels, up to 2664 pg/mL
(median 37.3 pg/mL), compared to a maximum of 84.4 pg/
mL (median 14.1 pg/mL) in sCAD. A relationship could not
be detected between background levels and demographics or
clinical parameters, such as severity of the coronary syndrome
based on total coronary obstruction as estimated during acute
angiography.
Bioanalytical causes for this phenomenon were not found,
neither could the high background levels be related to the
interval between sample collection and processing. Albeit true
that a time dependent decrease in cytokine response was ob-
served, a prolonged interval was not associated with higher
background levels, and judging from the ratios, the overall
effects of ETC-216, MDCO-216, and LPS in these samples
were consistent with the results obtained from samples that
were processed immediately after collection (data not shown).
Statistical significance was reached for the population dif-
ferences in MDCO-216 and LPS stimulated results, based on
an analysis of variance of the ln-transformed ratios over
background (unstimulated) cytokine levels, which included
sex as covariate. For LPS, the difference in TNF-α ratios
between the sCAD and HV population was 206% (95% con-
fidence interval [CI]: 120–355, p = 0.0057), between aCAD
and HV 40% (24–68, p = 0.0002), and between aCAD and
sCAD 19% (11–33, p < 10−9). For MDCO-216 only the dif-
ference between sCAD and aCAD populations was statistical-
ly significant (IL-6: ratio 69% [95%-CI: 50–95], p = 0.0170;
TNF-α: ratio 67% [48–94], p = 0.0169). Other covariates
were not found to have a statistically significant effect, nor
improved the model fit.
Population differences were difficult to test statistically for
the ETC-216 stimulated condition and IL-6 results following
LPS stimulation, due tomany stimulated cytokine levels being
>ULOQ. Analysing a reduced dataset which only included
values <ULOQ resulted in underpowered comparisons.
Attempts to fit a multinomial regression model after
categorising the data failed for the same reason.
In Vivo Exposure
Table 2 lists the baseline characteristics of the populations
exposed to MDCO-216 in vivo. The most commonly used
medication by stable CAD patients was an antithrombotic
agent (96%), mainly acetylsalicylic acid (83%). Statins were
used by 92%, β-blockers by 58%, and ACE-inhibitors by
38% of the patients.
In the HV population exposed toMDCO-216, two subjects
complained of abdominal pain or distension, one (50%) in the
10 mg/kg group and one (25%) in the 20 mg/kg group, which
started 9 h after administration. Stable CAD patients receiving
MDCO-216, reported nausea once (4 h post dose, 20 mg/kg
group) and diarrhoea once (13 h post dose, 40 mg/kg). The
latter case was a patient who had undergone a cholecystecto-
my and since then regularly developed diarrhoea after
ingesting high-fat meals.
No inflammatory reaction was observed in HVand sCAD
patients, judging by body temperature, white cell counts, neu-
trophil counts, C-reactive protein, and circulating cytokines
(Fig. 1).
Discussion
Recombinant proteins represent a powerful class of drugs that
is employed to supplement absent or insufficient quantities of
essential enzymes, hormones, and coagulation factors.
Additionally, peptides can be designed to specifically interact
with cells or receptors and thus interfere in the pathophysiol-
ogy of certain diseases [11–13].
However, since these proteins or peptides are invariably
expressed in allogeneic, often non-human, cell systems for-
eign material is released into the medium together with the
Table 3 Ex vivo results
HV sCAD aCAD
(n = 35) (n = 35) (n = 35)
IL-6
LPS 797.7 (1.9) 933.5 (2.0) 62.1 (6.5)
ETC-216* 15.8 (2.9) 9.5 (3.6) 3.8 (4.0)
MDCO-216 0.8 (1.9) 0.7 (1.5) 1.0 (2.0)
TNF-α
LPS 117.4 (1.9) 242.0 (1.8) 46.9 (4.0)
ETC-216* 9.0 (2.8) 6.0 (3.8) 3.5 (4.0)
MDCO-216 0.8 (1.8) 0.7 (1.9) 1.0 (2.0)
Geometric mean (standard deviation) of ratios of LPS, ETC-216 and
MDCO-216 stimulated cytokine concentration over unstimulated (back-
ground) levels for IL-6 and TNF-α
*Ratios are underestimated as a result of stimulated samples being
>ULOQ: for IL-6 in 26 (74.3%) HV, 19 (54.3%) sCAD, 16 (45.7%)
aCAD; and for TNF-α in 20 (57.1%) HV, 24 (68.6%) sCAD, 6 (17.1%)
aCAD Patients with acute coronary artery disease (CAD); HV Healthy
volunteers; LPS Lipopolysaccharide; sCAD Patients with stable coronary
artery disease (CAD); ULOQ Upper limit of quantitation
386 Cardiovasc Drugs Ther (2017) 31:381–389
protein of interest. Countless impurities can trigger the im-
mune system; especially bacterial based platforms, such as
those using Escherichia coli, are notorious suppliers of
immunostimulatory impurities like endotoxin (lipopolysac-
charide or LPS) [14]. Also the remaining proteins in a phar-
maceutical, collectively referred to as host cell proteins
(HCP), can potentially elicit an inflammatory reaction [15].
ETC-216, expressed in E. coli, was approved for intrave-
nous administration to humans in accordance with all
pertaining regulatory guidelines. Specifically, the limulus
amebocyte lysate (LAL) test was negative, HCP levels were
≤10 ppm, and each dose contained <10 ng of residual DNA.
Nevertheless, administration of ETC-216 to healthy volun-
teers induced dose-dependent neutrophilic leucocytosis, in-
creases in body temperature, and gastrointestinal side effects.
In CAD patients, hypersensitivity-like reactions were ob-
served as well as gastrointestinal side effects. In retrospect,
these findings are easily recognised as signs and symptoms
of an inflammatory response caused by the HCP impurities.
After several modifications were made to the manufactur-
ing process to reduce the HCP levels, the recombinant ApoA-
IM was reintroduced as MDCO-216. Because it was deemed
unethical to expose a human population to a product with a
known immunostimulatory propensity (ETC-216), an ex vivo
whole blood incubation assay was applied to compare differ-
ences in cytokine response to MDCO-216 and ETC-216.
Results demonstrated that ETC-216 clearly induced cyto-
kine release, in contrast to MDCO-216. In HV and sCAD
patients, MDCO-216 even slightly inhibited (spontaneous)
release. This difference was statistically significant for all pop-
ulations, with p-values ≤0.0005. The observed inhibition of
approximately 30% byMDCO-216 is in accordance with pre-
vious studies that have reported that HDL or HDL-like parti-
cles display many anti-inflammatory properties [16].
The absence of an inflammatory reaction was confirmed in
a clinical trial with MDCO-216. No increases in neutrophils
were observed following MDCO-216 infusion in HV and
sCAD patients. Also, the more sensitive biomarkers (CRP
and circulating cytokines) did not suggest immune stimulation
by MDCO-216. Additionally, the observed gastrointestinal
side effects did not display a dose-relationship as was seen
for ETC-216, although it should be noted that MDCO-216
was infused at a lower rate compared to ETC-216.
An interesting question to be asked is whether an ex vivo
incubation assay can be implemented to detect adverse im-
mune stimulation. Certainly, a whole blood stimulation test
can detect a myriad of pyrogenic substances, such as LPS,
porins, lipoteichoic acid (LTA) and peptidoglycan [17–22].
Nonetheless, many uncertainties still surround the interpreta-
tion of its result [23]. Our results revealed differences in reac-
tivity between the three tested populations, not only with re-
gard to the HCP impurities in ETC-216, but also to LPS,
which highlights some of the uncertainties.
For example, LPS stimulation resulted in higher cytokine
responses in sCAD patients compared to HV, and ETC-216
induced lower levels in sCAD patients compared to HV. After
correction for the differences in monocyte count, the statisti-
cally significant differences remained. Other factors, such as
age, BMI, and blood pressure could not explain any of the
found effects.
Comorbidities may have influenced the response, as – for
example – hypertension was previously found byDörffel et al.
[24] to increase TNF-α and IL-1β secretion from peripheral
blood monocytes after in vitro LPS stimulation by >50%,
although these patients were untreated. The antihypertensives
losartan, captopril, and amlodipine dose-dependently reduced
IL-1β release induced by LPS, but not below LPS stimulated
levels in normotensive subjects [25].
Other cardiovascular medications are also known to influ-
ence the (innate) immune response. For example, certain cal-
cium channel blockers were observed to interfere with both
flagellin and LPS signalling [26, 27]. Statins and aspirin dem-
onstrate similar anti-inflammatory properties [28–30].
Interestingly however, whereas many cardiovascular drugs
inhibit TLR-4 mediated responses, with β-blockers being a
notable exception [31, 32], ex vivo LPS stimulation induced
higher cytokine levels in sCAD patients than in HV. Although
effects of certain cardiovascular medications and conditions
on toll-like receptor (TLR) signalling have not been examined
as extensively for TLR-5 (flagellin) as for TLR-4 (LPS), our
results suggest that the response to flagellin and other HCP
impurities can be modified by these factors as well.
Notwithstanding the aforementioned effects, compared to
stable CAD patients, acute CAD patients displayed higher
background cytokine levels, as well as an overall diminished
responsiveness to both LPS and ETC-216. Severity of the
coronary disease, based on total obstruction, or the coronary
involved was not related to background cytokine levels, or
any of the observed effects after ex vivo stimulation with
LPS, ETC-216 or MDCO-216.
ACS is associated with elevated plasma levels of pro-
inflammatory cytokines, chemokines, and leucocytes, which
are governed at least partly by TLR-4 stimulation [33, 34].
Conversely, stress hormones such as catecholamines and hy-
drocortisone, that have a general immune-inhibiting mode of
action, are increased in parallel [35–37]. This combination
might explain both the high background cytokine levels and
the reduced response to ETC-216 observed in the aCAD pa-
tients. TLR-4 mediated cytokine release in ACS can also ac-
count for the observation that a subsequent (experimental)
LPS challenge did only modestly increase IL-6 and TNF-α
concentrations ex vivo.
It should be stressed, however, that although (the conse-
quences of) an inflammatory response can be influenced by
external factors, a reduced response is not synonymous with
an improved outcome, especially in critically ill patients. This
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warrants a cautious approach when exposing (vulnerable)
humans to an experimental biologic. Furthermore, it under-
lines the current limitations of an ex vivo stimulation test in
reliably predicting inflammatory reactions upon in vivo ad-
ministration in the target population, although it can be used
to highlight differences between two pharmacological prod-
ucts within a population.
Concluding, MDCO-216 does not elicit an acute immune
response in healthy volunteers nor in patients with stable cor-
onary artery disease, in contrast to what was previously ob-
served with ETC-216. Results from an ex vivo stimulation
with both products suggests the same holds true for patients
with an acute coronary syndrome.
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